LL schreef op 14 mei 2023 11:45:
[...]
Roep maar niet te hard ;)
China
Our collaboration with China State Institute of
Pharmaceutical Industry (CSIPI) and the Chengdu Institute
of Biological Products (CDIBP), both Sinopharm companies,
continues to progress. This collaboration includes
development and commercialization rights for RUCONEST®
in China. The RUCONEST® manufacturing process and
quality system has been transferred to Sinopharm, enabling
future manufacture for China. The arrangement provides for
Pharming to receive certain regulatory and manufacturingassociated
milestones, and low to mid-single digit
royalties from sales in China by CDIBP or other affiliates of
Sinopharm.
bron:
Jaarverslag 2022